Trump to visit Fed on Thursday amid Powell feud, renovation probe
On Wednesday, H.C. Wainwright maintained a Buy rating on Personalis (NASDAQ:PSNL) and raised the price target to $9.00 from the previous $8.00. The adjustment follows Personalis’ first-quarter financial report on Tuesday, which revealed total revenues of $20.6 million, surpassing the consensus estimate of $17.4 million. According to InvestingPro data, the company has demonstrated impressive momentum with a 153% return over the past year, despite showing some volatility in recent trading.
Personalis experienced significant growth in its NeXT Personal molecular tests, which saw a 52% increase to 2,184 tests in the first quarter of 2025, up from 1,441 in the fourth quarter of 2024. This growth reflects strong demand and contributes to the company’s positive performance. InvestingPro data shows the company maintains a healthy financial position with a current ratio of 6.52, indicating strong ability to meet short-term obligations.
The company’s minimal residual disease (MRD) platform within the biopharma business segment is also gaining traction. Both existing and new customers are increasingly adopting the MRD platform, indicating a broader acceptance and integration of Personalis’ offerings in the biopharma industry.
In response to the company’s performance and market trends, H.C. Wainwright has made several adjustments to its financial model. The firm extended its financial projections to the year 2032, previously set to 2030. Additionally, it projects that Personalis’ total revenues will grow from $85.9 million in 2025 to $654.2 million by 2032.
The raised 12-month price target to $9 per diluted share reflects the analyst’s confidence in Personalis’ continued growth and the expanded adoption of its molecular tests and MRD platform. The revised target is based on the company’s current achievements and the expected trajectory of its revenue growth over the coming years. Discover more insights about Personalis and access detailed financial analysis through the comprehensive Pro Research Report, available exclusively on InvestingPro, along with 8 additional ProTips and extensive financial metrics.
In other recent news, Personalis Inc . reported its Q1 2025 earnings, surpassing analyst expectations. The company achieved an earnings per share (EPS) of -$0.18, outperforming the forecast of -$0.25, and reported revenues of $20.6 million, exceeding the expected $17.5 million. This marks a significant improvement, with a 39% year-over-year increase in biopharma revenue. The company’s gross margin also improved to 35%, up from 28.1% the previous year. Personalis launched the NextPersonal MRD test, contributing to its growth, and announced a strategic partnership with Tempus for sales and marketing. The company provided revenue guidance of $80-90 million for 2025, anticipating a 30-40% increase in molecular tests. Analysts are optimistic about Personalis’ potential for future growth, particularly in the MRD market, expected to mature to $20 billion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.